Compumedics Share Price Up Big on FDA Approval (ASX: CMP)

By ,

At time of writing, the share price of Compumedics Ltd [ASX:CMP] is up a significant 25.47%, trading at 87 cents.

It’s been a remarkable 12 months for the stock, with the Compumedics share price rising a total of 154% during this period:

Compumedics Share Price Chart - ASX CMP


We look at what triggered this move, which involves an important FDA clearance for Compumedics’ product.

Share price up on important FDA clearance

The market greeted the announcement today by pushing the Compumedics share price higher from the start of trading.

It’s an important step for the company as it allows for their Magnetoencephalography (MEG) device to be used in a routine clinical setting. This is mainly to be used for epilepsy and pre-surgical brain function mapping.

The company hopes now that their MEG product will grow to be as widely used as MRIs.

There are 36,000 MRIs installed globally, Compumedics notes.

The machines come in at a price point of between US$3 million and US$4 million.

So if the company is right — you can see that there is a potentially massive addressable market there.

Which goes a long way to explaining what happened to Compumedics’ share price today.

You can see what the product looks like below:

Magnetoencephalography Device - Compumedics MEG Device FDA Approval

Source: newswire

Around 1.2% or 3.4 million people have epilepsy in the US.

In the short term, with such a sharp share price rise, it is conceivable Compumedics may pull back somewhat over the coming days, with investors taking profits after a strong 12-month period.

That being said, the medtech space continues to excite with other big-name winners including companies like PolyNovo Ltd [ASX:PNV].

If this field excites you, be sure to read our free report which picks out three small-caps that could take off this year. One of the picks merges AI with medical imaging — something particularly relevant considering today’s Compumedics announcement.


Lachlann Tierney,
For Money Morning

About Lachlann Tierney

Lachlann Tierney is an Analyst for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest…

PolyNovo Shares Surges 25% on Strong 1H22 Sales Growth (ASX:PNV)

PolyNovo [ASX:PNV] shares are rising today after the biotech stock reported its indicative half-year trading results.

PolyNovo Share Price in Reverse upon New Funding (ASX:PNV)

Shares in Melbourne-based medtech company Polynovo Ltd [ASX:PNV] have slid for a fifth consecutive day. Today’s dip in the PNV share price comes on the back of new funding for clinical trials of its proprietary NovoSorb regeneration solution…

PolyNovo Share Price Up as Study Results Encourage Market (ASX:PNV)

After an initial fall in line with the COVID-19 influence on the ASX 200 [XJO], the PolyNovo Ltd [ASX:PNV] share price shot up 66.27% from its low to close at $2.12, at the time of writing. PolyNovo is an Australian-based medical device company…